2023-508444-22-00撤回1 期
An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)
Region Midtjylland2 个研究点 分布在 2 个国家目标入组 30 人开始时间: 2024年4月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 30
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Department of Infectious Diseases
Scientific
Region Midtjylland
研究点 (2)
Loading locations...
相似试验
招募中
1 期
An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)2023-508444-22-01Region Midtjylland30
已完成
1 期
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy ParticipantsRespiratory syncytial virus infection2022-502926-42-00Merck Sharp & Dohme LLC32
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors2024-515504-39-00Centre Hospitalier Universitaire De Nantes6
已完成
1 期
A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis2024-513639-26-00F. Hoffmann-La Roche AG44
已完成
1 期
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapy2024-511853-23-00Oncoinvent ASA54